Are the Days of Unfettered Pharmaceutical Pricing Gone?

Jack Bailey, President of GlaxoSmithKline Plc’s U.S. Pharmaceuticals, is working on bringing new drugs to market as efficiently as possible and says the days of unfettered pricing are done. Read more here. (Source: Cynthia Koons, Bloomberg Business, 2/11/16)

You might also be interested in:

AMCP Names Cynthia Reilly as Senior VP May 23, 2018
Bloomberg Offers Price Indexes for Widely-Used Drugs July 19, 2018
Bloomberg Analysis: PBMs Got Major Markup in New York January 26, 2019
Report: Physicians Play Key Role in Lower Drug Prices July 28, 2018
Trump White House Applies More Pressure on Pharma to Negotiate… August 13, 2018
Is Trump’s Fight Against Drug Prices Gaining Steam? July 20, 2018
FDA’s RWE Framework Could Push Pharma to Reshape Strategies December 20, 2018